GeneSystem Co

GeneSystem Co Current Assets

The Current Assets of GeneSystem Co (363250.KQ) as of Oct 29, 2026 is 648.59 M KRW. In the previous year, Current Assets was 9.80 B KRW — a change of -93.38% (lower).

Current Assets

648.59 MKRW

YoY

-93.38%

Last updated:

Current Assets of GeneSystem Co is 2025 648.59 M KRW. Current Assets of GeneSystem Co was 2024 9.80 B KRW. It decreases by -93.38% lower compared to the previous year.

The GeneSystem Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
3.60 B KRW
Jan 1, 2019
1.41 B KRW
Jan 1, 2020
11.26 B KRW
Jan 1, 2021
41.45 B KRW
Jan 1, 2022
30.38 B KRW
Jan 1, 2023
20.77 B KRW
Jan 1, 2024
9.80 B KRW
Jan 1, 2025
648.59 M KRW
The GeneSystem Co Current Assets history
YEARCurrent AssetsYoY
648.59 MKRW-93.38%
9.80 BKRW-52.84%
20.77 BKRW-31.61%
30.38 BKRW-26.71%
41.45 BKRW+268.00%
11.26 BKRW+698.58%
1.41 BKRW-60.78%
3.60 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

Current Assets of GeneSystem Co is 648.59 M KRW in 2025.

Current Assets of GeneSystem Co changed from 9.80 B KRW to 648.59 M KRW, representing a -93.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's GeneSystem Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GeneSystem Co

All Key Metrics — GeneSystem Co